Table 1.
Overview of the study groups and rat characteristics at the end of the study period.
| SHR | STZ-SHR | |||||
|---|---|---|---|---|---|---|
| Control (n = 8) | Vildagliptin (n = 8) | Metformin (n = 6) | Control (n = 7) | Vildagliptin (n = 7) | Metformin (n = 7) | |
| body weight (g) | 333 ± 5 | 348 ± 7 | 309 ± 10# | 282 ± 6* | 273 ± 11 | 243 ± 8# |
| food intake (g·day−1) | 12.8 ± 1.8 | 15.5 ± 0.4 | 13.8 ± 2.9 | 22.1 ± 2.0* | 24.6 ± 4.0 | 16.1 ± 2.7 |
| water intake (ml·day−1) | 31.4 ± 2.1 | 28.4 ± 1.5 | 10.0 ± 2.3# | 66.3 ± 9.1* | 80.6 ± 18.9 | 31.3 ± 5.0# |
| urine volume (ml·day−1) | 17.5 ± 1.9 | 15.6 ± 1.2 | 4.5 ± 0.6# | 48.3 ± 7.9* | 68.9 ± 18.0 | 24.2 ± 5.4# |
| blood glucose (mmol l·L−1) | 9.9 ± 0.3 | 9.6 ± 0.6 | 8.1 ± 0.7 | 20.9 ± 2.4* | 25.9 ± 2.8 | 23.4 ± 0.8 |
| HbA1c (%) | 3.71 ± 0.03 | 3.90 ± 0.07 | 3.78 ± 0.17 | 8.09 ± 0.34* | 8.70 ± 0.55 | 7.31 ± 0.23 |
| triglycerides (mmol·L−1) | 0.80 ± 0.002 | 1.17 ± 0.29 | 0.95 ± 0.06 | 2.09 ± 0.30* | 1.91 ± 0.32 | 1.90 ± 0.23 |
| liver: body weight (mg·g−1) | 34.9 ± 0.5 | 34.8 ± 0.8 | 34.8 ± 0.9 | 49.0 ± 1.2* | 49.5 ± 1.1 | 48.0 ± 1.1 |
| left kidney: body weight (mg·g−1) | 3.85 ± 0.15 | 3.91 ± 0.30 | 4.17 ± 0.22 | 5.13 ± 0.31* | 5.26 ± 0.14 | 4.99 ± 0.13 |
| albumin excretion (mg·24 h−1) | 9.5 ± 1.7 | 13.1 ± 2.9 | 25.5 ± 6.3# | 28.4 ± 7.3* | 23.8 ± 8.1 | 46.9 ± 6.7 |
| systolic blood pressure (mmHg) | 149 ± 6 | 119 ± 9# | 112 ± 18# | 134 ± 9 | 111 ± 7 | 92 ± 12# |
Data are mean ± SEM. *p < 0.05 STZ-SHR vs. control SHR; #p < 0.05 treatment vs. appropriate control.